Johnson & Johnson Balance Sheet

(In Millions of USD)

Year 2009 2008

Cash & Equivalents 15,810.00 10,768.00
Short Term Investments 3,615.00 2,041.00
Cash and Short Term Investments 19,425.00 12,809.00
Accounts Receivable - Trade, Net 9,646.00 9,719.00
Receivables - Other - -
Total Receivables, Net 9,646.00 9,719.00
Total Inventory 5,180.00 5,052.00
Prepaid Expenses 2,497.00 3,367.00
Other Current Assets, Total 2,793.00 3,430.00
Total Current Assets 39,541.00 34,377.00
Property/Plant/Equipment, Total - Gross 29,251.00 27,392.00
Accumulated Depreciation, Total -14,492.00 -13,027.00
Goodwill, Net 14,862.00 13,719.00
Intangibles, Net 16,323.00 13,976.00
Long Term Investments - 4
Other Long Term Assets, Total 9,197.00 8,471.00
Total Assets 94,682.00 84,912.00
Accounts Payable 5,541.00 7,503.00
Accrued Expenses 9,430.00 9,200.00
Notes Payable/Short Term Debt 6,318.00 3,732.00
Current Port. of LT Debt/Capital Leases - -
Other Current liabilities, Total 442 417
Total Current Liabilities 21,731.00 20,852.00
Long Term Debt 8,223.00 8,120.00
Capital Lease Obligations - -
Total Long Term Debt 8,223.00 8,120.00
Total Debt 14,541.00 11,852.00
Deferred Income Tax 1,424.00 1,432.00
Minority Interest - -
Other Liabilities, Total 12,716.00 11,997.00
Total Liabilities 44,094.00 42,401.00
Redeemable Preferred Stock, Total - -
Preferred Stock - Non Redeemable, Net - -
Common Stock, Total 3,120.00 3,120.00
Additional Paid-In Capital - -
Retained Earnings (Accumulated Deficit) 70,306.00 63,379.00
Treasury Stock - Common -19,780.00 -19,033.00
Other Equity, Total -3,058.00 -4,955.00
Total Equity 50,588.00 42,511.00
Total Liabilities & Shareholders' Equity 94,682.00 84,912.00
Shares Outs - Common Stock Primary Issue - -
Total Common Shares Outstanding 2,754.32 2,769.18
 2007 2006
7,770.00 4,083.00
1,545.00 1
9,315.00 4,084.00
9,444.00 8,712.00
- -
9,444.00 8,712.00
5,110.00 4,889.00
3,467.00 3,196.00
2,609.00 2,094.00
29,945.00 22,975.00
26,466.00 24,028.00
-12,281.00 -10,984.00
14,123.00 13,340.00
14,640.00 15,348.00
2 16
8,059.00 5,833.00
80,954.00 70,556.00
6,909.00 5,691.00
10,242.00 8,167.00
2,463.00 4,579.00
- -
223 724
19,837.00 19,161.00
7,074.00 2,014.00
- -
7,074.00 2,014.00
9,537.00 6,593.00
1,493.00 1,319.00
- -
9,231.00 8,744.00
37,635.00 31,238.00
 - -
- -
3,120.00 3,120.00
- 0
55,280.00 49,290.00
-14,388.00 -10,974.00
-693 -2,118.00
43,319.00 39,318.00
80,954.00 70,556.00
- -
2,840.22 2,893.23
 Johnson & Johnson Income Statement
(In Millions of USD)

Year 2009 2008

Revenue 61,897.00 63,747.00
Other Revenue, Total - -
Total Revenue 61,897.00 63,747.00
Cost of Revenue, Total 18,447.00 18,511.00
Gross Profit 43,450.00 45,236.00
Selling/General/Admin. Expenses, Total 19,801.00 21,490.00
Research & Development 6,986.00 7,577.00
Depreciation/Amortization - -
Interest Expense(Income) - Net Operating - -
Unusual Expense (Income) 1,073.00 181
Other Operating Expenses, Total -526 -1,015.00
Total Operating Expense 46,142.00 46,818.00
Operating Income 15,755.00 16,929.00
Interest Income(Expense), Net Non-Operating - -
Gain (Loss) on Sale of Assets - -
Other, Net - -
Income Before Tax 15,755.00 16,929.00
Income After Tax 12,266.00 12,949.00
Minority Interest - -
Equity In Affiliates - -
Net Income Before Extra. Items 12,266.00 12,949.00
Accounting Change - -
Discontinued Operations - -
Extraordinary Item - -
Net Income 12,266.00 12,949.00
Preferred Dividends - -
nt

2007 2006
61,095.00 53,324.00
- -
61,095.00 53,324.00
17,751.00 15,057.00
43,344.00 38,267.00
20,451.00 17,433.00
7,680.00 7,125.00
- -
- -
1,552.00 559
534 -671
47,812.00 38,737.00
13,283.00 14,587.00
- -
- -
- -
13,283.00 14,587.00
10,576.00 11,053.00
- -
- -
10,576.00 11,053.00
- -
- -
- -
10,576.00 11,053.00
- -
 GlaxoSmithKline Balance Sheet
(In Millions of GBP)

Year 2009 2008

Cash & Equivalents - -
Short Term Investments 5,957.00 5,362.00
Cash and Short Term Investments 6,813.00 6,014.00
Accounts Receivable - Trade, Net 5,486.00 5,333.00
Receivables - Other - -
Total Receivables, Net 6,248.00 6,046.00
Total Inventory 4,064.00 4,056.00
Prepaid Expenses 302 295
Other Current Assets, Total 143 858
Total Current Assets 17,570.00 17,269.00
Property/Plant/Equipment, Total - Gross 18,757.00 18,987.00
Accumulated Depreciation, Total -9,383.00 -9,309.00
Goodwill, Net 3,361.00 2,101.00
Intangibles, Net 8,183.00 5,869.00
Long Term Investments 1,349.00 1,030.00
Other Long Term Assets, Total 2,764.00 3,199.00
Total Assets 42,862.00 39,393.00
Accounts Payable 1,855.00 1,153.00
Accrued Expenses 4,481.00 4,586.00
Notes Payable/Short Term Debt 1,471.00 956
Current Port. of LT Debt/Capital Leases - -
Other Current liabilities, Total 4,311.00 3,322.00
Total Current Liabilities 12,118.00 10,017.00
Long Term Debt 14,696.00 15,143.00
Capital Lease Obligations 90 88
Total Long Term Debt 14,786.00 15,231.00
Total Debt 16,257.00 16,187.00
Deferred Income Tax 645 714
Minority Interest 737 387
Other Liabilities, Total 4,571.00 5,113.00
Total Liabilities 32,857.00 31,462.00
Redeemable Preferred Stock, Total - -
Preferred Stock - Non Redeemable, Net - -
Common Stock, Total 1,416.00 1,415.00
Additional Paid-In Capital 1,368.00 1,326.00
Retained Earnings (Accumulated Deficit) 8,343.00 5,190.00
Treasury Stock - Common - -
Other Equity, Total - -
Total Equity 10,005.00 7,931.00
Total Liabilities & Shareholders' Equity 42,862.00 39,393.00
Shares Outs - Common Stock Primary Issue - -
Total Common Shares Outstanding 5,073.20 5,058.51
 2007 2006
- -
3,905.00 2,420.00
4,532.00 3,040.00
4,649.00 4,356.00
- -
5,314.00 5,199.00
3,062.00 2,437.00
239 224
479 92
13,626.00 10,992.00
15,087.00 13,443.00
-7,266.00 -6,513.00
1,370.00 758
4,456.00 3,293.00
846 736
2,723.00 2,844.00
31,003.00 25,553.00
931 865
3,668.00 3,654.00
3,504.00 718
- -
2,242.00 2,028.00
10,345.00 7,265.00
7,067.00 4,772.00
- -
7,067.00 4,772.00
10,571.00 5,490.00
887 595
307 262
2,794.00 3,273.00
21,400.00 16,167.00
 - -
- -
1,503.00 1,498.00
1,266.00 858
6,834.00 7,030.00
- -
- -
9,603.00 9,386.00
31,003.00 25,553.00
- -
6,012.59 5,756.12
 GlaxoSmithKline Income Statement
(In Millions of GBP)

Year 2009 2008

Revenue 28,368.00 24,352.00
Other Revenue, Total - -
Total Revenue 28,368.00 24,352.00
Cost of Revenue, Total 7,380.00 5,776.00
Gross Profit 20,988.00 18,576.00
Selling/General/Admin. Expenses, Total 9,200.00 7,352.00
Research & Development 3,951.00 3,506.00
Depreciation/Amortization - -
Interest Expense(Income) - Net Operating - -
Unusual Expense (Income) -150 926
Other Operating Expenses, Total -440 -321
Total Operating Expense 19,946.00 17,216.00
Operating Income 8,422.00 7,136.00
Interest Income(Expense), Net Non-Operating - -
Gain (Loss) on Sale of Assets 115 -
Other, Net 2 -10
Income Before Tax 7,891.00 6,659.00
Income After Tax 5,669.00 4,712.00
Minority Interest -138 -110
Equity In Affiliates - -
Net Income Before Extra. Items 5,531.00 4,602.00
Accounting Change - -
Discontinued Operations - -
Extraordinary Item - -
Net Income 5,531.00 4,602.00
Preferred Dividends - -
 2007 2006
22,716.00 23,225.00
- -
22,716.00 23,225.00
5,206.00 5,010.00
17,510.00 18,215.00
6,817.00 7,257.00
3,237.00 3,457.00
- -
- -
176 -137
-240 -123
15,123.00 15,417.00
7,593.00 7,808.00
- -
- -
-26 -35
7,452.00 7,799.00
5,310.00 5,498.00
-96 -109
- -
5,214.00 5,389.00
- -
- -
- -
5,214.00 5,389.00
- -
 Turnover Ratios

Ratio Formula

Receivables Turnover

Payables Turnover

Inventory Turnover

Asset Turnover
Turnover Ratios

Year 2009 2008 2007 2006

J&J 6.3926671830622 6.6531336429578 6.7300066093853 -
GSK 5.2441075885017 4.8791825285514 5.0451971127152 -
J&J 2.8088009812941 2.5768803774632 2.7825396825397 -
GSK 4.9015957446809 4.5892514395394 5.1013363028953 -
J&J 3.6057466770915 3.6431804762842 3.5505550555056 -
GSK 1.8177339901478 1.6229277887047 1.8934351700309 -
J&J 0.6537356625335 0.7507419446015 0.7546878474195 0.7557684676002
GSK 0.661844990901 0.6181808950829 0.7327032867787 0.9088952373498